Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $29.00 and last traded at $26.98, with a volume of 379019 shares trading hands. The stock had previously closed at $28.69.
Gemini Therapeutics Stock Up 0.1 %
The business’s 50-day simple moving average is $53.77 and its 200 day simple moving average is $54.92. The firm has a market capitalization of $1.17 billion, a P/E ratio of -27.00 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- How to Calculate Options Profits
- High-Yield Texas Instruments Could Hit New Highs Soon
- Transportation Stocks Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
